WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center

Clearing 19 biologics for Europe market

FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough

The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year

Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

The fast growing pharma industry in India offers us a wide range of opportunities and we represent the world's leading technology providers in india

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Fortis Escorts Faridabad launches dedicated pacemaker clinic

Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation

Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350

DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036

Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

EMA backs conditional EU nod for Vijoice in rare life-threatening overgrowth disorder PROS

The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients